搜索
Nervgen Pharma Ord Shs
NGEN添加自选
2.120USD
+0.030+1.44%
收盘 07/02, 13:00（美东）报价延迟15分钟
171.78M总市值
亏损市盈率 TTM
关于 Nervgen Pharma Ord Shs 公司
NervGen Pharma Corp. is a clinical-stage biotech company. The Company is engaged in developing treatments to promote nervous system repair in the settings of neurotrauma and neurologic disease. NVG-291 is in a Phase 1b/2a clinical trial in spinal cord injury and has undertaken preclinical evaluation of a new development candidate, NVG-300, in models of ischemic stroke, amyotrophic lateral sclerosis (ALS) and spinal cord injury (SCI). Its NVG-291 is a therapeutic peptide targeting nervous system repair.
Nervgen Pharma Ord Shs简介
公司代码NGEN
公司名称NervGen Pharma Corp
上市日期Mar 13, 2019
CEORogers (Adam H)
员工数量- -
证券类型Ordinary Share
年结日- -
公司地址Suite 1703 - 595 Burrard Street
城市VANCOUVER
上市交易所NASDAQ OMX - NASDAQ BASIC
国家Canada
邮编V7X 1J1
电话16047225361
网址https://www.nervgen.com/
公司代码NGEN
上市日期Mar 13, 2019
CEORogers (Adam H)
Nervgen Pharma Ord Shs公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Randall E. Kaye, M.D.
Dr. Randall E. Kaye, M.D.
Independent Director
Independent Director
160.00K
-31.25%
Ms. Krista L. Mckerracher
Ms. Krista L. Mckerracher
Independent Director
Independent Director
27.76K
-54.04%
,
,
--
--
Mr. Brian Eric Bayley
Mr. Brian Eric Bayley
Independent Director
Independent Director
--
--
Dr. Harold Martin Punnett
Dr. Harold Martin Punnett
Independent Director
Independent Director
--
--
Mr. William J. (Bill) Adams
Mr. William J. (Bill) Adams
Chief Financial Officer, Corporate Secretary
Chief Financial Officer, Corporate Secretary
--
--
Dr. Daniel D. (Dan) Mikol, M.D., Ph.D
Dr. Daniel D. (Dan) Mikol, M.D., Ph.D
Chief Medical Officer
Chief Medical Officer
--
--
Mr. John Craig Thompson
Mr. John Craig Thompson
Independent Director
Independent Director
--
--
Dr. Adam H. Rogers
Dr. Adam H. Rogers
Chairman of the Board, Interim Chief Executive Officer
Chairman of the Board, Interim Chief Executive Officer
--
--
Mr. Gianni (John) Ruffolo
Mr. Gianni (John) Ruffolo
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Randall E. Kaye, M.D.
Dr. Randall E. Kaye, M.D.
Independent Director
Independent Director
160.00K
-31.25%
Ms. Krista L. Mckerracher
Ms. Krista L. Mckerracher
Independent Director
Independent Director
27.76K
-54.04%
,
,
--
--
Mr. Brian Eric Bayley
Mr. Brian Eric Bayley
Independent Director
Independent Director
--
--
Dr. Harold Martin Punnett
Dr. Harold Martin Punnett
Independent Director
Independent Director
--
--
Mr. William J. (Bill) Adams
Mr. William J. (Bill) Adams
Chief Financial Officer, Corporate Secretary
Chief Financial Officer, Corporate Secretary
--
--
常见问题
Nervgen Pharma Ord Shs的前五大股东是谁？
Nervgen Pharma Ord Shs 的前五大股东如下：Dr. Randall E. Kaye, M.D.
有多少机构持有Nervgen Pharma Ord Shs(NGEN)的股份？
截至2026Q1，共有17家机构持有Nervgen Pharma Ord Shs的股份，合计持有的股份价值约为350.93K，占公司总股份的0.44%。与2025Q4相比，机构持股有所增加，增幅为303132.00。